Online first
Review paper
Published online: 2023-09-22

open access

Page views 404
Article views/downloads 117
Get Citation

Connect on Social Media

Connect on Social Media

Pembrolizumab in combination with chemotherapy in patients with advanced squamous cell lung cancer — clinical trials and real-world data

Magdalena Knetki-Wróblewska1, Dariusz M. Kowalski1

Abstract

Advanced squamous-cell lung carcinoma remains a disease with an unfavorable prognosis. Until recently, chemotherapy was used in systemic treatment, and its effectiveness was limited. Implementation of immune check-point inhibitors allowed for an improvement in treatment results. The KEYNOTE-407 study included patients with squamous-cell lung cancer who received 4 immunochemotherapy cycles followed by maintenance treatment with pembrolizumab. Median overall survival of 17.2 months versus 11.6 months for chemotherapy was obtained (risk of death reduction by 29%) while the percentage of patients remaining in follow-up was 18%. Analysis of patients with good performance status treated in clinical practice confirms the results from the registration study and emphasizes the importance of taking into consideration clinical factors while qualifying patients for treatment.

Article available in PDF format

View PDF Download PDF file

References

  1. https://onkologia.org.pl/pl/raporty.
  2. Hendriks LE, Kerr KM, Menis J, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(4): 358–376.
  3. Knetki-Wroblewska M, Wiśniewski P, Szatkowska-Tomczyk A, et al. 207P Does age affect PD-L1 expression? Results of a single-center analysis of a large cohort of patients. Journal of Thoracic Oncology. 2023; 18(4): S152.
  4. Bailey H, Lee A, Eccles L, et al. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey. BMC Cancer. 2023; 23(1): 603.
  5. Gousis C, Josephides E, McGrath H, et al. 147P Changes in demographic and smoking history trends in patients referred to a London thoracic malignancy specialist centre between 2010–2021: The Guy’s Cancer Centre experience. Journal of Thoracic Oncology. 2023; 18(4): S122.
  6. Paz-Ares L, Luft A, Vicente D, et al. KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21): 2040–2051.
  7. Paz-Ares L, Vicente D, Tafreshi A, et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol. 2020; 15(10): 1657–1669.
  8. Novello S, Kowalski DM, Luft A, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023; 41(11): 1999–2006.
  9. Waterhouse D, Lam J, Betts KA, et al. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 2021; 156: 41–49.
  10. Liu SV, Rai P, Wang D, et al. First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices. JTO Clin Res Rep. 2023; 4(2): 100444.
  11. Banna GL, Cantale O, Muthuramalingam S, et al. Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. Int Immunopharmacol. 2022; 110: 108985.
  12. Wagenius G, Vikström A, Berglund A, et al. 51P Real-word outcomes of immunotherapy in non-small cell lung cancer: A population-based cohort study in Sweden. Journal of Thoracic Oncology. 2023; 18(4): S71–S72.
  13. Anpalakhan S, Huddar P, Behrouzi R, et al. Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis. Front Oncol. 2023; 13: 1163768.
  14. Borghaei H, Gettinger S, Vokes EE, et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021; 39(7): 723–733.
  15. Mazieres J, Rittmeyer A, Gadgeel S, et al. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. J Thorac Oncol. 2021; 16(1): 140–150.
  16. Sonehara K, Ozawa R, Hama M, et al. Predictive Factors Associated with Long-Term Response to Combination Immunotherapy in Patients with Untreated Advanced Non-Small-Cell Lung Cancer: A Multicenter Retrospective Study. Oncology. 2023 [Epub ahead of print]: 1–10.
  17. Xiong A, Xu J, Wang S, et al. On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer. Front Immunol. 2023; 14: 1173025.
  18. Rebuzzi SE, Prelaj A, Friedlaender A, et al. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Crit Rev Oncol Hematol. 2022; 179: 103806.
  19. Antoun S, Lanoy E, Ammari S, et al. Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. Eur J Cancer. 2023; 178: 49–59.
  20. Mouritzen MT, Carus A, Ladekarl M, et al. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy. Cancers (Basel). 2021; 13(19).